Translation. Region: Russian Federation –
Source: People's Republic of China in Russian – People's Republic of China in Russian –
An important disclaimer is at the bottom of this article.
Source: People's Republic of China – State Council News
BEIJING, Oct. 18 (Xinhua) — Construction of a new insulin active pharmaceutical ingredient (API) production base, in which French pharmaceutical giant Sanofi has invested a total of 1 billion euros (about 1.16 billion U.S. dollars), began in the Beijing Economic and Technological Development Zone on Friday.
This is not only Sanofi's largest single investment in China to date, but also the largest investment project in the pharmaceutical sector in the Chinese capital. The nearly 60,000-square-meter project is expected to be completed and operational by 2032.
According to Brendan O'Callaghan, Sanofi's Executive Vice President, Manufacturing and Supply Chain, thanks to innovative reforms underway in China, this base will become one of Sanofi's most technologically advanced and digitally advanced manufacturing facilities in the world, and will comprehensively implement green manufacturing practices.
The new project, together with Sanofi's existing production bases in Beijing, Shenzhen, and Hangzhou, will form a high-quality manufacturing network covering various areas, from API production to drug development, allowing the company to better meet the needs of Chinese patients and advance diabetes prevention and treatment together with its local partners, said Shi Wang, General Manager of Sanofi's Greater China Region. -0-
Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.